Vigilant Capital Management’s AstraZeneca AZN Stock Holding History

Vigilant Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$30.1M	Sell	209,726 -102	-0%	-$15K	2.25%	17
2023 Q1	$29.2M	Sell	209,828 -4,289	-2%	-$577K	2.37%	13
2022 Q4	$29.1M	Sell	214,117 -4,152	-2%	-$521K	2.49%	14
2022 Q3	$24M	Sell	218,269 -1,401	-0.6%	-$178K	2.25%	18
2022 Q2	$29.1M	Sell	219,670 -782	-0.4%	-$103K	2.51%	11
2022 Q1	$29.3M	Buy	220,452 +4,820	+2%	+$578K	2.23%	14
2021 Q4	$25.1M	Buy	215,632 +14,977	+7%	+$1.76M	1.76%	27
2021 Q3	$24.1M	Buy	200,655 +14,391	+8%	+$1.68M	1.93%	20
2021 Q2	$22.3M	Buy	186,264 +2,395	+1%	+$263K	1.8%	27
2021 Q1	$18.3M	Buy	183,869 +6,802	+4%	+$684K	1.63%	37
2020 Q4	$17.7M	Buy	177,067 +6,292	+4%	+$666K	1.7%	32
2020 Q3	$18.7M	Buy	170,775 +5,192	+3%	+$577K	2.05%	24
2020 Q2	$17.5M	Buy	165,583 +1,754	+1%	+$181K	2.13%	21
2020 Q1	$14.6M	Buy	163,829 +5,535	+3%	+$521K	2.13%	20
2019 Q4	$15.8M	Sell	158,294 -1,262	-0.8%	-$119K	1.83%	28
2019 Q3	$14.2M	Buy	159,556 +6,328	+4%	+$549K	1.85%	34
2019 Q2	$12.7M	Buy	153,228 +13,248	+9%	+$1.04M	1.69%	38
2019 Q1	$11.3M	Buy	139,980 +139,580	+34,895%	+$11M	1.58%	40
2018 Q4	$30K	Hold	400	–	–	﹤0.01%	291
2018 Q3	$32K	Hold	400	–	–	﹤0.01%	316
2018 Q2	$28K	Sell	400 -104	-21%	-$7.48K	﹤0.01%	312
2018 Q1	$35K	Buy	504 +104	+26%	+$7.2K	0.01%	258
2017 Q4	$28K	Hold	400	–	–	﹤0.01%	274
2017 Q3	$27K	Hold	400	–	–	﹤0.01%	219
2017 Q2	$27K	Hold	400	–	–	﹤0.01%	197
2017 Q1	$25K	Hold	400	–	–	﹤0.01%	202
2016 Q4	$22K	Buy	+400	New	+$22.7K	﹤0.01%	214

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vigilant Capital Management's AZN Position: Q2 2023 in Review

Vigilant Capital Management reduced its AstraZeneca (AZN) stake by 0.05% in Q2 2023, selling an estimated $15K and leaving 209,726 shares worth $30.1M. The position accounts for 2.25% of the portfolio, ranked #17.

Vigilant Capital Management first reported a position in AZN in Q4 2016 and has held it in 27 quarters since. 1,091 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Vigilant Capital Management held 209,726 shares of AstraZeneca worth $30.1M as of Q2 2023.
Vigilant Capital Management sold 102 AstraZeneca shares in Q2 2023, an estimated $15K.
AstraZeneca made up 2.25% of Vigilant Capital Management's portfolio in Q2 2023, its #17 holding.
Vigilant Capital Management first reported a position in AstraZeneca in Q4 2016 and has held it in 27 quarters since.
1,091 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.